- Record: found
- Abstract: not found
- Article: not found
Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-Ll/CTLA-4 bispecific antibody) in patients (pts) with HER2 aberrated solid tumors
2020
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.